The importance microRNAs as a biomarker in lung cancer

Main Article Content

Duran Canatan
Yonca Sonmez
Ozlem Yılmaz
Hasan Şenol Coşkun
Sema Sezgin Göksu
Selda Uçar
Mehmet Rıfkı Aktekin


microRNA, biomarker, lung cancer


Introduction: Lung cancer (LC) is the most common cancer  in the world.Well known  causes are  long term  smoking, environmental influences and genetic variations. LC  is divided into two main types based on their histological phenotypes; small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC). The high specificity of these new screening methods, which are non-invasive, safe, inexpensive and simple to perform, is important in the early diagnosis and prognosis of cancer. MicroRNAs are  significant biomarkers on the diagnosis metastasis and targeted therapies of NSCLC. In our study, we aimed to investigate the potential of using microRNAs as a biomarker in the early diagnosis of lung cancer.

Material and method: Twenty patients diagnosed with lung cancer and  twenty healthy individuals of the same age and gender were selected as the control group.  Sixteen microRNAs were studied from blood samples.

Result: Sixteen miRNAs (Let -7c, Let-7g, miR-1, miR-21, miR-29a, miR-31, miR-34a, miR 103a, miR-141, miR-155, miR-193b, miR-200b, miR-205, miR-340, miR-486, miR-708) were selected for tests and MiR 181 and miR 192 were used as the endogenous control group in line with their binding potentials and gene expression levels. The most specific and sensitive miRNAs were mirR-29a, miR-103a, and miR486 according to endogen controls in patients and healthy subjects.

Discussion: A meta-analysis study showed that circulating miRNAs could be promising biomarkers for early diagnosis of lung cancer. Overall, 17 studies were included evaluating 35 miRNA markers and 19 miRNA panels in serum or plasma. The potential role of circulating miRNAs for non-invasive lung screening has been highlighted.

In conclusion, there is a need for further validation studies for the use of three  miRNAs as a biomarker in the early diagnosis and prognosis of lung cancer.


Download data is not yet available.
Abstract 157 | PDF Downloads 129


1. Bray F, Ferlay J, Soerjomataram I, Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clin. 2018,68, 394–424.
2. Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanan P. Lung cancer: Biology and treatment options.Biochim. Biophys. Acta (BBA)-Rev. Cancer 2015, 1856, 189–210.
3. Ahn YH and Ko YH. Diagnostic and Therapeutic Implications of microRNAs in Non-Small Cell Lung Cancer. Int. J. Mol. Sci. 2020, 21, 8782; doi:10.3390/ijms21228782.
4. Sheervalilou R, Lotfi H, Shirvaliloo M, Sharifi A, Nazemiyeh M, Zarghami N. Circulating MiR-10b, MiR-1 and MiR-30a Expression Profiles in Lung Cancer: Possible Correlation with Clinico-pathologic Characteristics and Lung Cancer Detection Int J Mol Cell Med. Spring 2019;8(2):118-129. doi: 10.22088/IJMCM.BUMS.8.2.118. Epub 2019 Aug 20.
5. Gasparri R, Romano R, Sedda G, Diagnostic biomarkers for lung cancer prevention. J Breath Res. 2018 Feb 6;12(2):027111. doi: 10.1088/1752-7163/aa9386.
6. Wu KL,Tsai YM, Lien CT, Kuo PL, Hung AJ. The Roles of MicroRNA in Lung Cancer. Mol Sci. 2019 Mar 31;20(7). pii: E1611. doi: 10.3390/ijms20071611.
7. Pratap P, Raza ST, Abbas S, Mahdi F. MicroRNA-associated carcinogenesis in lung carcinoma. J Cancer Res Ther. 2018 Jan-Mar;14(2):249-254. doi: 10.4103/0973-1482.187283.
8. Li L, Sun Y, Feng M, Wang L, Liu J.Clinical significance of blood-based miRNAs as biomarkers of non-small cell lung cancer. Oncol Lett. 2018 Jun;15(6):8915-8925. doi: 10.3892/ol.2018.8469. Epub 2018 Apr 12.
9. Zhou Q, Huang SX, Zhang F, MicroRNAs: A novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer. Cell Prolif. 2017 Dec;50(6). doi: 10.1111/cpr.12394. Epub 2017 Oct 8.
10. Canatan D, Yılmaz Ö, Sönmez Y, Çim A, Coşkun HŞ, Göksu SS, Circulating microRNAs as Potential Non-invasive Biomarkers for Breast Cancer Detection. Acta Biomed 2021; Vol. 92, N. 2: e2021028 DOI: 10.23750/abm. v92i2.9678.
11. Hajian-Tilaki K. Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation. Caspian J Intern Med. 2013;4(2):627-35.
12 Iqbal MA, Arora S, Prakasam G, Calin GA, Syed MA. MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance. Mol Aspects Med. 2019 Dec; 70:3-20. doi: 10.1016/j.mam.2018.07.003. Epub 2018 Aug 18.
13. Świtlik WZ, Szemraj J. Circulating miRNAs as non-invasive biomarkers for non-small cell lung cancer diagnosis, prognosis and prediction of treatment response. Postepy Hig Med Dosw (Online). 2017 Aug 9;71(0):649-662.
14. Inamura K. Diagnostic and Therapeutic Potential of MicroRNAs in Lung Cancer. Cancers (Basel). 2017 May 9;9(5). pii: E49. doi: 10.3390/cancers9050049.
15. Inamura K, Ishikawa Y. MicroRNA In Lung Cancer: Novel Biomarkers and Potential Tools for Treatment. J Clin Med. 2016 Mar 9;5(3). pii: E36. doi: 10.3390/jcm5030036.
16. Bica-Pop C, Cojocneanu-Petric R, Magdo L Raduly L, Gulei D, Berindan-Neagoe I. Overview upon miR-21 in lung cancer: focus on NSCLC. Cell Mol Life Sci. 2018 Oct;75(19):3539-3551. doi: 10.1007/s00018-018-2877-x. Epub 2018 Jul 20.
17. Nadal E, Truini A, Nakata A, A Novel Serum 4-microRNA Signature for Lung Cancer Detection. Sci Rep, 2015; 5: 12464.DOI: 10.1038/srep12464.
18. Yu H, Guan Z, Cuk K, Brenner H, Zhang Y. Circulating microRNA biomarkers for lung cancer detection in Western populations. Cancer Med. 2018 Oct;7(10):4849-4862. doi: 10.1002/cam4.1782. Epub 2018 Sep 27.
19. Xue J Yang J, Luo M, Cho WC, Liu X. MicroRNA-targeted therapeutics for lung cancer treatment. Expert Opin Drug Discov. 2017 Feb;12(2):141-157. doi: 10.1080/17460441.2017.1263298. Epub 2016 Nov 28.

Most read articles by the same author(s)

1 2 > >>